← All stocks

Damora Therapeutics, Inc.

DMRA Net selling
CIK 0001800315 #2097 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$30.65K
$0.00 on a plan · $23.31K straight out of an exercise
Sold at will
$7.35K
1 of 4 sales
Net
−$30.65K
−$7.35K against sales at will

By person

8 insiders · 4 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Schambye Hans T.
Chief Executive Officer
$14.97K (1) scheduled
−$14.97K
4,682
$140.37K
+123.2%
Winslow Garrett
General Counsel
$12.80K (2)
−$12.80K
2,289
$68.62K
+1,331%
Firmani Lori
Chief Financial Officer
$2.89K (1) scheduled
−$2.89K
931
$27.91K
Fairmount Funds Management LLC entity
Director
2,904,000
$87.06M
Jarrett Jennifer
See Remarks
500,000
$14.99M
Hewes L. Becker
Chief Medical Officer
264,629
$7.93M
Sattarzadeh Sherwin
Chief Operating Officer
190,376
$5.71M
Bruno Julianne
Director
137,032
$4.11M
+1,606%

No percentages here. This company's share count has moved by a factor of 46.9 over the window, from 1,316,989 to 61,735,519 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Firmani Lori
2 Jan 2026
Chief Financial Officer
Sold after exercise
135
$21.41
$2.89K
Winslow Garrett
2 Jan 2026
General Counsel
Sold after exercise
255
$21.38
$5.45K
Schambye Hans T.
2 Jan 2026
Chief Executive Officer
Sold after exercise
700
$21.38
$14.97K

What was left out

Form 4 filings counted 16
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 3
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 9,800,099
History held since 4 Nov 2020